The second clinical trial relied on the use of Talazoparib for breast cancer patients positive for BRCA1/2 pathogenic mutations with either locally advanced or metastatic cancers (EMBRACA) [43]. Here, BRCA1 is linked to metastatic malignant neoplasm.